We're taking a closer look at Baxter International today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 3.8% compared to 0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
-
Baxter International has moved -6.1% over the last year compared to 11.7% for the S&P 500 -- a difference of -17.9%
-
BAX has an average analyst rating of hold and is -18.16% away from its mean target price of $38.34 per share
-
Its trailing 12 month earnings per share (EPS) is $-0.52
-
Baxter International has a trailing 12 month Price to Earnings (P/E) ratio of -60.3 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $2.88 and its forward P/E ratio is 10.9
-
The company has a Price to Book (P/B) ratio of 2.27 in contrast to the S&P 500's average ratio of 4.74
-
Baxter International is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
-
Baxter International has on average reported free cash flows of $1.13 Billion over the last four years, during which time they have grown by an an average of -14.9%
